Eric Dishman does health care research for Intel -- studying how new technology can solve big problems in the system for the sick, the aging and, well, all of us.
Eric Dishman is an Intel Fellow and general manager of Intel's Health Strategy & Solutions Group. He founded the product research and innovation team responsible for driving Intel’s worldwide healthcare research, new product innovation, strategic planning, and health policy and standards activities.
Dishman is recognized globally for driving healthcare reform through home and community-based technologies and services, with a focus on enabling independent living for seniors. His work has been featured in The New York Times, Washington Post and Businessweek, and The Wall Street Journal named him one of “12 People Who Are Changing Your Retirement.” He has delivered keynotes on independent living for events such as the annual Consumer Electronics Show, the IAHSA International Conference and the National Governors Association. He has published numerous articles on independent living technologies and co-authored government reports on health information technologies and health reform.
He has co-founded organizations devoted to advancing independent living, including the Technology Research for Independent Living Centre, the Center for Aging Services Technologies, the Everyday Technologies for Alzheimer’s Care program, and the Oregon Center for Aging & Technology.
“[Modern health care] is a very reactive, crisis-driven system.”
“Computing used to be an expert-driven system; it [became] a personal system that we all owned as part of our daily lives. That shift from mainframe to personal computing is what we have to do for health care.”
“Health care is treating us as averages, not unique individuals, [but] at the end of the day, the patient is not the same thing as the population.”
“We have got to untether clinicians and patients from the notion of traveling to a special bricks-and-mortar place for all of our care, because these places are often the wrong tool, and the most expensive tool, for the job.”
“On my chart, I forced [my doctors] to put, ‘Patient goal: low doses of drugs over longer periods of time, side effects friendly to skiing.’ And I think that's why I achieved longevity. I think that time-in-snow therapy was as important as the pharmaceuticals that I had.”